{"id":"W3213899689","doi":"10.1016/s2152-2650(21)02101-7","title":"OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Pomalidomide; Fludarabine; Internal medicine; Bortezomib; Carfilzomib; Rituximab; Daratumumab; Regimen; Multiple myeloma; Refractory (planetary science); Clinical endpoint; Oncology; Cyclophosphamide; Gastroenterology; Surgery; Clinical trial; Chemotherapy; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002483273,0.0008240682,0.001585092,0.001283141,0.0001950953,0.001550763,0.001072112,0.0009684003,0.004464169],"category_scores_gemma":[0.001370108,0.0002816289,0.001222589,0.001619771,0.0003151829,0.0008332042,0.0004854364,0.00165495,0.001997622],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001314145,"about_ca_system_score_gemma":0.001816529,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003133851,"about_ca_topic_score_gemma":0.008295297,"domain_scores_codex":[0.9993314,0.0001482877,0.00008020483,0.0000785952,0.0002630335,0.00009856157],"domain_scores_gemma":[0.9992108,0.0002011873,0.000231934,0.00003649222,0.0001859679,0.0001335639],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.008845086,0.0007092827,0.00304839,0.002788462,0.001119986,0.0002674711,0.00005597956,0.0007964784,0.01161993,0.0004653085,0.05566582,0.9146178],"study_design_scores_gemma":[0.0139965,0.009978224,0.03727027,0.001841987,0.006877864,0.002596817,0.00009153974,0.001008426,0.0161805,0.0007269999,0.9092966,0.0001343802],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.08312242,0.8555853,0.003621048,0.0117005,0.002418305,0.000807429,0.01471958,0.0008001731,0.02722528],"genre_scores_gemma":[0.20896,0.6863752,0.01337141,0.01633438,0.002214569,0.001135646,0.04991982,0.0003201906,0.02136883],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.004464169,"threshold_uncertainty_score":0.01493418,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03591386775633376,"score_gpt":0.310774505472544,"score_spread":0.2748606377162102,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}